Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 6 of 6 results for baloxavir marboxil

  1. Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal) (TA732)

    NICE is unable to make a recommendation on baloxavir marboxil (Xofluza) for treating acute uncomplicated influenza in people aged 12 and over. This is because Roche did not provide an evidence submission.

    Sections for TA732

  2. Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]

    Awaiting development Reference number: GID-TA10684 Expected publication date: TBC

  3. Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]

    Awaiting development Reference number: GID-TA10683 Expected publication date: TBC

  4. Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years [ID6554]

    Topic prioritisation

  5. Baloxavir marboxil for treating influenza in babies under 1 year [ID6555]

    In development Reference number: GID-TA11712 Expected publication date: TBC

  6. Baloxavir marboxil for reducing direct transmission of influenza A or B in people 5 to 64 years [ID6552]

    In development Reference number: GID-TA11646 Expected publication date: TBC